APO Research
Talk to an analyst

APO RESEARCH · REPORT

Metachromatic Leukodystrophy (MLD) Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Metachromatic Leukodystrophy (MLD) Treatment Market Analysis and Forecast 2026-2032

22 December 2025194 pages

Choose your research edition.

Industry ResearchMetachromatic Leukodystrophy (MLD) Treatment Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Metachromatic Leukodystrophy (MLD) Treatment Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Metachromatic Leukodystrophy (MLD) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metachromatic Leukodystrophy (MLD) Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Metachromatic Leukodystrophy (MLD) Treatment Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Metachromatic Leukodystrophy (MLD) Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Metachromatic Leukodystrophy (MLD) Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Metachromatic Leukodystrophy (MLD) Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Metachromatic Leukodystrophy (MLD) Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Metachromatic Leukodystrophy (MLD) Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Metachromatic Leukodystrophy (MLD) Treatment include Takeda, GlaxoSmithKline Plc, RegenxBio Inc, Recursion Pharmaceuticals Inc and ArmaGen Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Metachromatic Leukodystrophy (MLD) Treatment, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Metachromatic Leukodystrophy (MLD) Treatment, also provides the sales of main regions and countries. Of the upcoming market potential for Metachromatic Leukodystrophy (MLD) Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Metachromatic Leukodystrophy (MLD) Treatment sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Metachromatic Leukodystrophy (MLD) Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Metachromatic Leukodystrophy (MLD) Treatment sales, projected growth trends, production technology, application and end-user industry.

Metachromatic Leukodystrophy (MLD) Treatment Segment by Company

Takeda

GlaxoSmithKline Plc

RegenxBio Inc

Recursion Pharmaceuticals Inc

ArmaGen Inc

Metachromatic Leukodystrophy (MLD) Treatment Segment by Type

AGT-183

DUOC-01

GSK-2696274

Others

Metachromatic Leukodystrophy (MLD) Treatment Segment by Application

Hospital

Clinic

Others

Metachromatic Leukodystrophy (MLD) Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metachromatic Leukodystrophy (MLD) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metachromatic Leukodystrophy (MLD) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metachromatic Leukodystrophy (MLD) Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Metachromatic Leukodystrophy (MLD) Treatment in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Metachromatic Leukodystrophy (MLD) Treatment manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Metachromatic Leukodystrophy (MLD) Treatment sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. AGT-183 Major Manufacturers Table 3. DUOC-01 Major Manufacturers Table 4. GSK-2696274 Major Manufacturers Table 5. Others Major Manufacturers Table 6. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Manufacturers Table 8. Clinic Major Manufacturers Table 9. Others Major Manufacturers Table 10. Metachromatic Leukodystrophy (MLD) Treatment Industry Trends Table 11. Metachromatic Leukodystrophy (MLD) Treatment Industry Drivers Table 12. Metachromatic Leukodystrophy (MLD) Treatment Industry Opportunities and Challenges Table 13. Metachromatic Leukodystrophy (MLD) Treatment Industry Restraints Table 14. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region (2021-2026) Table 18. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region (2027-2032) Table 19. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 20. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2021-2026) & (k units) Table 21. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2027-2032) & (k units) Table 22. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2021-2026) Table 23. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2027-2032) Table 24. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Manufacturers (2021-2026) Table 28. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Price (US$/unit) of Manufacturers (2021-2026) Table 29. Global Metachromatic Leukodystrophy (MLD) Treatment Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Metachromatic Leukodystrophy (MLD) Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Metachromatic Leukodystrophy (MLD) Treatment Manufacturers, Product Type & Application Table 32. Global Metachromatic Leukodystrophy (MLD) Treatment Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Metachromatic Leukodystrophy (MLD) Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2021-2026) Table 39. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2027-2032) Table 40. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type 2021 VS 2025 VS 2032 (k units) Table 41. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (k units) Table 42. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2027-2032) & (k units) Table 43. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2021-2026) Table 44. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2027-2032) Table 45. Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2021-2026) & (US$/unit) Table 46. Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2027-2032) & (US$/unit) Table 47. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2021-2026) Table 51. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2027-2032) Table 52. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application 2021 VS 2025 VS 2032 (k units) Table 53. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (k units) Table 54. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2027-2032) & (k units) Table 55. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2021-2026) Table 56. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2027-2032) Table 57. Global Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2021-2026) & (US$/unit) Table 58. Global Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2027-2032) & (US$/unit) Table 59. Takeda Company Information Table 60. Takeda Business Overview Table 61. Takeda Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 62. Takeda Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio Table 63. Takeda Recent Development Table 64. GlaxoSmithKline Plc Company Information Table 65. GlaxoSmithKline Plc Business Overview Table 66. GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio Table 68. GlaxoSmithKline Plc Recent Development Table 69. RegenxBio Inc Company Information Table 70. RegenxBio Inc Business Overview Table 71. RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio Table 73. RegenxBio Inc Recent Development Table 74. Recursion Pharmaceuticals Inc Company Information Table 75. Recursion Pharmaceuticals Inc Business Overview Table 76. Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio Table 78. Recursion Pharmaceuticals Inc Recent Development Table 79. ArmaGen Inc Company Information Table 80. ArmaGen Inc Business Overview Table 81. ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio Table 83. ArmaGen Inc Recent Development Table 84. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 85. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 86. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (k units) Table 87. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2027-2032) & (k units) Table 88. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Type (2021-2026) & (US$/unit) Table 89. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Type (2027-2032) & (US$/unit) Table 90. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 91. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 92. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (k units) Table 93. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2027-2032) & (k units) Table 94. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Application (2021-2026) & (US$/unit) Table 95. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Application (2027-2032) & (US$/unit) Table 96. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 98. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 99. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 100. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026) & (k units) Table 101. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2027-2032) & (k units) Table 102. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Country (2021-2026) & (US$/unit) Table 103. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Country (2027-2032) & (US$/unit) Table 104. United States Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 105. Canada Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 106. Mexico Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 107. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 108. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 109. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (k units) Table 110. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2027-2032) & (k units) Table 111. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Type (2021-2026) & (US$/unit) Table 112. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Type (2027-2032) & (US$/unit) Table 113. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 114. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 115. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (k units) Table 116. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2027-2032) & (k units) Table 117. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Application (2021-2026) & (US$/unit) Table 118. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Application (2027-2032) & (US$/unit) Table 119. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 121. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 122. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 123. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026) & (k units) Table 124. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2027-2032) & (k units) Table 125. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Country (2021-2026) & (US$/unit) Table 126. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Country (2027-2032) & (US$/unit) Table 127. Germany Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 128. France Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 129. U.K. Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 130. Italy Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 131. Russia Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 132. Spain Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 133. Netherlands Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 134. Switzerland Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 135. Sweden Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 136. Poland Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 137. China Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 138. China Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 139. China Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (k units) Table 140. China Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2027-2032) & (k units) Table 141. China Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Type (2021-2026) & (US$/unit) Table 142. China Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Type (2027-2032) & (US$/unit) Table 143. China Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 144. China Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 145. China Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (k units) Table 146. China Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2027-2032) & (k units) Table 147. China Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Application (2021-2026) & (US$/unit) Table 148. China Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Application (2027-2032) & (US$/unit) Table 149. Asia Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 150. Asia Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 151. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (k units) Table 152. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2027-2032) & (k units) Table 153. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Type (2021-2026) & (US$/unit) Table 154. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Type (2027-2032) & (US$/unit) Table 155. Asia Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 156. Asia Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 157. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (k units) Table 158. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2027-2032) & (k units) Table 159. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Application (2021-2026) & (US$/unit) Table 160. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Application (2027-2032) & (US$/unit) Table 161. Asia Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. Asia Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 163. Asia Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 164. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 165. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026) & (k units) Table 166. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2027-2032) & (k units) Table 167. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Country (2021-2026) & (US$/unit) Table 168. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Country (2027-2032) & (US$/unit) Table 169. Japan Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 170. South Korea Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 171. India Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 172. Australia Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 173. Taiwan Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 174. Southeast Asia Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 175. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 176. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 177. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2026) & (k units) Table 178. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2027-2032) & (k units) Table 179. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Type (2021-2026) & (US$/unit) Table 180. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Type (2027-2032) & (US$/unit) Table 181. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 182. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 183. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2026) & (k units) Table 184. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2027-2032) & (k units) Table 185. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Application (2021-2026) & (US$/unit) Table 186. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Application (2027-2032) & (US$/unit) Table 187. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 188. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 189. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 190. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 191. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2026) & (k units) Table 192. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2027-2032) & (k units) Table 193. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Country (2021-2026) & (US$/unit) Table 194. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Country (2027-2032) & (US$/unit) Table 195. Brazil Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 196. Argentina Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 197. Chile Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 198. Colombia Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 199. Peru Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 200. Saudi Arabia Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 201. Israel Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 202. UAE Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 203. Turkey Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 204. Iran Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 205. Egypt Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Table 206. Key Raw Materials Table 207. Raw Materials Key Suppliers Table 208. Metachromatic Leukodystrophy (MLD) Treatment Distributors List Table 209. Metachromatic Leukodystrophy (MLD) Treatment Customers List Table 210. Research Programs/Design for This Report Table 211. Authors List of This Report Table 212. Secondary Sources Table 213. Primary Sources List of Figures Figure 1. Metachromatic Leukodystrophy (MLD) Treatment Image Figure 2. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. AGT-183 Image Figure 5. DUOC-01 Image Figure 6. GSK-2696274 Image Figure 7. Others Image Figure 8. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Others Image Figure 13. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue (2021-2032) & (US$ Million) Figure 15. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region (2021-2032) Figure 18. Global Metachromatic Leukodystrophy (MLD) Treatment Sales (2021-2032) & (k units) Figure 19. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 20. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Metachromatic Leukodystrophy (MLD) Treatment Sales YoY (2021-2032) & (k units) Figure 22. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales YoY (2021-2032) & (k units) Figure 23. China Metachromatic Leukodystrophy (MLD) Treatment Sales YoY (2021-2032) & (k units) Figure 24. Asia (Excluding China) Metachromatic Leukodystrophy (MLD) Treatment Sales YoY (2021-2032) & (k units) Figure 25. South America, Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales YoY (2021-2032) & (k units) Figure 26. Global Metachromatic Leukodystrophy (MLD) Treatment Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Metachromatic Leukodystrophy (MLD) Treatment Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2021-2032) Figure 32. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 33. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2021-2032) Figure 35. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2021-2032) Figure 38. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 39. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2021-2032) Figure 41. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Type (2021-2032) Figure 42. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Type (2021-2032) Figure 43. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Application (2021-2032) Figure 44. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Application (2021-2032) Figure 45. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Country (2021-2032) Figure 46. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Country (2021-2032) Figure 47. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Type (2021-2032) Figure 48. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Type (2021-2032) Figure 49. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Application (2021-2032) Figure 50. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Application (2021-2032) Figure 51. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Country (2021-2032) Figure 52. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Country (2021-2032) Figure 53. China Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Type (2021-2032) Figure 54. China Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Type (2021-2032) Figure 55. China Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Application (2021-2032) Figure 56. China Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Application (2021-2032) Figure 57. Asia Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Type (2021-2032) Figure 58. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Type (2021-2032) Figure 59. Asia Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Application (2021-2032) Figure 60. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Application (2021-2032) Figure 61. Asia Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Country (2021-2032) Figure 62. Asia Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Country (2021-2032) Figure 63. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Type (2021-2032) Figure 64. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Type (2021-2032) Figure 65. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Application (2021-2032) Figure 66. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Application (2021-2032) Figure 67. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Country (2021-2032) Figure 68. SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Country (2021-2032) Figure 69. Metachromatic Leukodystrophy (MLD) Treatment Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Metachromatic Leukodystrophy (MLD) Treatment Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • AGT-183
  • DUOC-01
  • GSK-2696274
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Takeda
  • GlaxoSmithKline Plc
  • RegenxBio Inc
  • Recursion Pharmaceuticals Inc
  • ArmaGen Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Metachromatic Leukodystrophy (MLD) Treatment Market by Type
  3. 1.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 AGT-183
  5. 1.2.3 DUOC-01
  6. 1.2.4 GSK-2696274
  7. 1.2.5 Others
  8. 1.3 Metachromatic Leukodystrophy (MLD) Treatment Market by Application
  9. 1.3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Metachromatic Leukodystrophy (MLD) Treatment Market Dynamics
  1. 2.1 Metachromatic Leukodystrophy (MLD) Treatment Industry Trends
  2. 2.2 Metachromatic Leukodystrophy (MLD) Treatment Industry Drivers
  3. 2.3 Metachromatic Leukodystrophy (MLD) Treatment Industry Opportunities and Challenges
  4. 2.4 Metachromatic Leukodystrophy (MLD) Treatment Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region
  3. 3.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2021-2026)
  5. 3.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2027-2032)
  6. 3.2.4 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region
  9. 3.4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2021-2026)
  11. 3.4.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2027-2032)
  12. 3.4.4 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Manufacturers
  2. 4.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Metachromatic Leukodystrophy (MLD) Treatment Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Manufacturers
  6. 4.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Metachromatic Leukodystrophy (MLD) Treatment Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Metachromatic Leukodystrophy (MLD) Treatment Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Metachromatic Leukodystrophy (MLD) Treatment Manufacturers, Product Type & Application
  13. 4.7 Global Metachromatic Leukodystrophy (MLD) Treatment Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market CR5 and HHI
  16. 4.8.2 2025 Metachromatic Leukodystrophy (MLD) Treatment Tier 1, Tier 2, and Tier 3
5 Metachromatic Leukodystrophy (MLD) Treatment Market by Type
  1. 5.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type
  2. 5.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type
  6. 5.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2021-2032)
  9. 5.3 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type
6 Metachromatic Leukodystrophy (MLD) Treatment Market by Application
  1. 6.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application
  2. 6.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application
  6. 6.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2021-2032)
  9. 6.3 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Application
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 GlaxoSmithKline Plc
  8. 7.2.1 GlaxoSmithKline Plc Company Information
  9. 7.2.2 GlaxoSmithKline Plc Business Overview
  10. 7.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
  12. 7.2.5 GlaxoSmithKline Plc Recent Developments
  13. 7.3 RegenxBio Inc
  14. 7.3.1 RegenxBio Inc Company Information
  15. 7.3.2 RegenxBio Inc Business Overview
  16. 7.3.3 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
  18. 7.3.5 RegenxBio Inc Recent Developments
  19. 7.4 Recursion Pharmaceuticals Inc
  20. 7.4.1 Recursion Pharmaceuticals Inc Company Information
  21. 7.4.2 Recursion Pharmaceuticals Inc Business Overview
  22. 7.4.3 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
  24. 7.4.5 Recursion Pharmaceuticals Inc Recent Developments
  25. 7.5 ArmaGen Inc
  26. 7.5.1 ArmaGen Inc Company Information
  27. 7.5.2 ArmaGen Inc Business Overview
  28. 7.5.3 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
  30. 7.5.5 ArmaGen Inc Recent Developments
8 North America
  1. 8.1 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
  2. 8.1.1 North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021-2032)
  3. 8.1.2 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2032)
  4. 8.1.3 North America Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2021-2032)
  5. 8.2 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
  6. 8.2.1 North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021-2032)
  7. 8.2.2 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2032)
  8. 8.2.3 North America Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2021-2032)
  9. 8.3 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
  10. 8.3.1 North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Metachromatic Leukodystrophy (MLD) Treatment Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
  2. 9.1.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021-2032)
  3. 9.1.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2032)
  4. 9.1.3 Europe Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2021-2032)
  5. 9.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
  6. 9.2.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021-2032)
  7. 9.2.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2032)
  8. 9.2.3 Europe Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2021-2032)
  9. 9.3 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
  10. 9.3.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Metachromatic Leukodystrophy (MLD) Treatment Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
  2. 10.1.1 China Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021-2032)
  3. 10.1.2 China Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2032)
  4. 10.1.3 China Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2021-2032)
  5. 10.2 China Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
  6. 10.2.1 China Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021-2032)
  7. 10.2.2 China Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2032)
  8. 10.2.3 China Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
  2. 11.1.1 Asia Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021-2032)
  3. 11.1.2 Asia Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2032)
  4. 11.1.3 Asia Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2021-2032)
  5. 11.2 Asia Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
  6. 11.2.1 Asia Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021-2032)
  7. 11.2.2 Asia Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2032)
  8. 11.2.3 Asia Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2021-2032)
  9. 11.3 Asia Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
  10. 11.3.1 Asia Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Metachromatic Leukodystrophy (MLD) Treatment Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Metachromatic Leukodystrophy (MLD) Treatment Market Size by Type
  2. 12.1.1 SAMEA Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2021-2032)
  5. 12.2 SAMEA Metachromatic Leukodystrophy (MLD) Treatment Market Size by Application
  6. 12.2.1 SAMEA Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2021-2032)
  9. 12.3 SAMEA Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country
  10. 12.3.1 SAMEA Metachromatic Leukodystrophy (MLD) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Metachromatic Leukodystrophy (MLD) Treatment Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Metachromatic Leukodystrophy (MLD) Treatment Value Chain Analysis
  2. 13.1.1 Metachromatic Leukodystrophy (MLD) Treatment Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Metachromatic Leukodystrophy (MLD) Treatment Production Mode & Process
  6. 13.2 Metachromatic Leukodystrophy (MLD) Treatment Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Metachromatic Leukodystrophy (MLD) Treatment Distributors
  9. 13.2.3 Metachromatic Leukodystrophy (MLD) Treatment Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst